The major objective to evaluate the function of blood monocytes from children with osteosarcoma and determine their ability to be activated by liposome-encapsulated immunomodulators to lyse tumor cells. In addition, we intend to monitor this monocyte function in each individual patient from the time of diagnosis, through chemotherapy and surgery and after all treatment. This project is based on the recent observation that normal human blood monocytes can be activated by liposome-encapsulated immunomodulators to selectively lyse malignant cells in vitro. Normal cells are not lysed under similar conditions or even when co-cultivated together with tumor cells. Furthermore, multiple intravenous injection of liposome-encapsulated activators into mice with well established spontaneous lung metastases have resulted in both the activation of pulmonary macrophages and the eradication of pulmonary metastases. Osteosarcoma appears an ideal disease in which to employ liposome-encapsulated immunomodulators since its natural history parallels that of the animal model used in these in vivo liposome studies. Despite removal of the primary bone tumor and the administration of adjuvant chemotherapy, approximately 40% of children with this disease develop pulmonary metastases. Our goal is to employ activated macrophages as an adjuvant therapy to eliminate residual tumor cells in the lung and we believe that patients with osteosarcoma may benefit from the inclusion of liposome-encapsulated immunomodulators as part of their therapy. However, prior to the initiation of any such therapy, it is imperative that the monocyte function of patients with osteosarcoma be evaluated, including the effects of chemotherapy, surgery and the tumor burden. Only then can we determine if all patients are candidates for such biological therapy and when is the ideal time to commence such adjuvant therapy. For example, if chemotherapy transiently depresses monocyte function, it will be important to know the time frame of the recovery phase before proposing in vivo treatment schedules with liposome-encapsulated monocyte activators. It is expected that these experiments will lay the groundwork for designing a protocol that includes liposome-encapsulated monocyte activators as a part of the adjuvant chemotherapy treatment not only for osteosarcoma, but possible for other malignancies as well.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042992-03
Application #
3184834
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1986-08-01
Project End
1990-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Yang, Yuanzheng; Huang, Gangxiong; Zhou, Zhichao et al. (2018) miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases. Mol Cancer Ther 17:130-139
Guma, Sergei R; Lee, Dean A; Yu, Ling et al. (2014) Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer 61:618-26
Rao-Bindal, Krithi; Rao, Chethan K; Yu, Ling et al. (2013) Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts. Pediatr Blood Cancer 60:575-9
Hollomon, Mario G; Gordon, Nancy; Santiago-O'Farrill, Janice M et al. (2013) Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells. BMC Cancer 13:500
Rao-Bindal, Krithi; Koshkina, Nadezhda V; Stewart, John et al. (2013) The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets 13:411-22
Huang, Gangxiong; Yu, Ling; Cooper, Laurence Jn et al. (2012) Genetically modified T cells targeting interleukin-11 receptor ?-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 72:271-81
Rao-Bindal, K; Zhou, Z; Kleinerman, E S (2012) MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death Dis 3:e369
Huang, Gangxiong; Nishimoto, Kazumasa; Zhou, Zhichao et al. (2012) miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 72:908-16
Koshkina, Nadezhda V; Rao-Bindal, Krithi; Kleinerman, Eugenie S (2011) Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 117:3457-67
Rodriguez Jr, Carlos O; Crabbs, Torrie A; Wilson, Dennis W et al. (2010) Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv 23:197-206

Showing the most recent 10 out of 79 publications